Market Overview

Theravance Confirms Favorable Ruling from FDA Panel on VIBATIV

Related THRX
Theravance, Inc. Appoints Theodore J. Witek, Jr. As Senior VP, Corporate Partnerships, Clinical And Medical Affairs
UPDATE: Stifel Downgrades Theravance Following Post-Split Accretion

Theravance Inc. (NASDAQ: THRX) today announced a favorable outcome of the Anti-Infective Drugs Advisory Committee (AIDAC) of the U.S. FDA meeting on VIBATIV(R) (telavancin) for the treatment of nosocomial pneumonia (NP) due to susceptible isolates of Gram-positive microorganisms.

Posted-In: News FDA

 

Most Popular

Related Articles (THRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free